Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Gynecologic 1

Conditions

Endometrial Neoplasms 12Polycystic Ovary Syndrome 4Endometrial Hyperplasia 4Infertility 3Neoplasms 2Anovulation 2Vitamin D Deficiency 1Turcot syndrome 1Overweight 1Obesity 1Menorrhagia 1Leiomyoma 1FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1Endometrial Adenocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Endometrioid 1Breast Neoplasms 1Advanced, Persistent, or Recurrent Endometrial Cancer 1Adenocarcinoma 1

Interventions

Exercise 6Counseling 6Nutrition Assessment 5Methods 3Diet Therapy 3Caloric Restriction 3Tirzepatide 2Resistance Training 2Naltrexone 2Metformin 2Megestrol Acetate 2Exenatide 2Educational Status 2Early Intervention, Educational 2Diet 2Cognitive Behavioral Therapy 2Bupropion 2sultamicillin 1semaglutide 1licogliflozin 1drospirenone and ethinyl estradiol combination 1drospirenone 1bupropion hydrochloride, naltrexone hydrochoride drug combination 1Ursodeoxycholic Acid 1Trehalase 1Tobacco Use Cessation Devices 1Tablets 1Surveys and Questionnaires 1Sugars 1Sucrose 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Overweight × Medroxyprogesterone Acetate × Clear all
NCT07462663 2026-05-13

SHAPE-ENDO

Hospital Universitari de Bellvitge

Phase 4 Not yet recruiting
82 enrolled
GynecologicOther

Endometrial Hyperplasia, Neoplasms, Obesity, Endometrial Neoplasms, Overweight

Data powered by HemOnc (CC BY 4.0) Colophon âš¡